Compare OCFC & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OCFC | SPRY |
|---|---|---|
| Founded | 1902 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 946.0M |
| IPO Year | 1996 | N/A |
| Metric | OCFC | SPRY |
|---|---|---|
| Price | $19.35 | $9.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $21.60 | ★ $31.25 |
| AVG Volume (30 Days) | 343.7K | ★ 2.4M |
| Earning Date | 01-22-2026 | 11-10-2025 |
| Dividend Yield | ★ 4.14% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.30 | N/A |
| Revenue | ★ $378,558,000.00 | $142,772,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.51 | $193.13 |
| P/E Ratio | $14.87 | ★ N/A |
| Revenue Growth | N/A | ★ 5459.66 |
| 52 Week Low | $14.29 | $6.66 |
| 52 Week High | $20.76 | $18.90 |
| Indicator | OCFC | SPRY |
|---|---|---|
| Relative Strength Index (RSI) | 61.62 | 58.71 |
| Support Level | $18.67 | $9.02 |
| Resistance Level | $19.66 | $9.76 |
| Average True Range (ATR) | 0.59 | 0.64 |
| MACD | 0.15 | 0.28 |
| Stochastic Oscillator | 86.97 | 92.30 |
OceanFirst Financial Corp is engaged in the banking sector of the United States. It conducts the business of attracting retail and business deposits and investing them in loans, consisting of single-family, owner-occupied residential mortgage loans, and commercial real estate loans. The company's sole segment deals with the delivery of loan and deposit products to customers. The bank's revenues are derived principally from interest on its loans, and to a lesser extent, interest on its investment and mortgage-backed securities. The rest of its income is dependent on bank card services and wealth management products and services.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.